Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical-stage biopharmaceutical company developing drugs for sexual dysfunction, inflammatory diseases and ophthalmological conditions has announced a manufacturing agreement with drug delivery maker Enthypharm Ltd for Zertane, Ampio’s drug for the treatment of premature ejaculation (PE).
Browsing: sexual dysfunction
On 9/22/09, BioSante and Cell Genesys (NASDAQ: CEGE) announced that they have determined the final exchange ratio will be 0.1828 in connection with the previously announced merger between the companies.